FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2319822019> ?p ?o ?g. }

• W2319822019 endingPage "580" @default.
• W2319822019 startingPage "580" @default.
• W2319822019 abstract "Introduction: MBV is a UL97 inhibitor with good oral bioavailability, low host cell toxicity and has theoretical benefits for inhibiting cross resistant viruses. We examined clinical and virological outcome of 9 patients treated with maribavir (MBV) in day to day use in France during 2011-2012. Methods: The CNR receives clinical information and resistance-suspected isolates from all transplant centers in France. During 2011-2012, 9 patients from 6 centers developed clinical (in 9/9) and/or genetic (in 6/9) resistance to CMV infection and were treated with maribavir (MBV). Data from these patients were collected including CMV viral load, resistance mutations in UL97 and UL54 genes, and clinical and virological responses to MBV therapy. Viral load was determined in each center using in house (n=3) or commercial assays (Argene n=2, Abbott n=1). Antiviral resistance (AVR) was determined by full-length sequencing of UL97 and UL54 genes using our published sequence-based methods, and GCV levels were measured when relevant. MBV response was considered adequate if viral load reduction was at least two logs or became undetectable. Results: Patients received bone marrow (n=3) and solid organ transplants (n=6 D+/R−) in 6 different centres, using similar standard immunosuppression regimens with CNI, mycophenolic acid, corticosteroids, with or without sirolimus. They received either ValGCV prophylaxis (n=5) or pre-emptive therapy (n=3), or ValACV prophylaxis (n=1). CMV UL97 or UL54 resistance mutations were present at the time of MBV treatment in 6 and 4 patients, respectively, without any MBV resistance mutation. Patients were given MBV in three cases following foscarnet (FOS) nephrotoxicity, in 1 case following UL54 mutation A809V which confers resistance to GCV/FOS, and in other cases for viral load plateauing on treatment. Two patients received MBV in association to FOS. An adequate MBV response was observed in 4/9 patients, with reduction in previously stable or increasing CMV viral load, in 5/9 patients there was either no response or uncertain response (slow decrease or efficient second prophylaxis) (see table) though clinical improvement in one patient. Conclusion: Our results showed good clinical and virological response to MBV in approximately half MBV-treated patients following CMV-resistant infection. There was variable response, although no clear parameter emerged as a clinical surrogate for non-response to MBV. These results are of great interest given the lack of efficacy in phase III trials of MBV prophylaxis in HSCT recipients, possibly due to low dosing regimens and drug initiation timing strategies used in the study. Additional clinical and surrogate laboratory markers are needed to determine antiviral response in order to guide MBV use, and dosage ranging studies would inform further MBV use.Table: [Summary table of MBV treated patients at six Frenc]" @default.
• W2319822019 created "2016-06-24" @default.
• W2319822019 creator A5001388711 @default.
• W2319822019 creator A5011238769 @default.
• W2319822019 creator A5012490285 @default.
• W2319822019 creator A5013487397 @default.
• W2319822019 creator A5028238948 @default.
• W2319822019 creator A5043187214 @default.
• W2319822019 creator A5043335832 @default.
• W2319822019 creator A5049845597 @default.
• W2319822019 creator A5051464876 @default.
• W2319822019 creator A5059401676 @default.
• W2319822019 creator A5061027575 @default.
• W2319822019 creator A5061063903 @default.
• W2319822019 creator A5075368769 @default.
• W2319822019 creator A5078717533 @default.
• W2319822019 creator A5086197485 @default.
• W2319822019 creator A5088063113 @default.
• W2319822019 creator A5091575574 @default.
• W2319822019 date "2012-11-01" @default.
• W2319822019 modified "2023-09-27" @default.
• W2319822019 title "MBV Use in Practice for Cytomegalovirus (CMV) Infection at Six French Transplant Centres" @default.
• W2319822019 doi "https://doi.org/10.1097/00007890-201211271-01121" @default.
• W2319822019 hasPublicationYear "2012" @default.
• W2319822019 type Work @default.
• W2319822019 sameAs 2319822019 @default.
• W2319822019 citedByCount "0" @default.
• W2319822019 crossrefType "journal-article" @default.
• W2319822019 hasAuthorship W2319822019A5001388711 @default.
• W2319822019 hasAuthorship W2319822019A5011238769 @default.
• W2319822019 hasAuthorship W2319822019A5012490285 @default.
• W2319822019 hasAuthorship W2319822019A5013487397 @default.
• W2319822019 hasAuthorship W2319822019A5028238948 @default.
• W2319822019 hasAuthorship W2319822019A5043187214 @default.
• W2319822019 hasAuthorship W2319822019A5043335832 @default.
• W2319822019 hasAuthorship W2319822019A5049845597 @default.
• W2319822019 hasAuthorship W2319822019A5051464876 @default.
• W2319822019 hasAuthorship W2319822019A5059401676 @default.
• W2319822019 hasAuthorship W2319822019A5061027575 @default.
• W2319822019 hasAuthorship W2319822019A5061063903 @default.
• W2319822019 hasAuthorship W2319822019A5075368769 @default.
• W2319822019 hasAuthorship W2319822019A5078717533 @default.
• W2319822019 hasAuthorship W2319822019A5086197485 @default.
• W2319822019 hasAuthorship W2319822019A5088063113 @default.
• W2319822019 hasAuthorship W2319822019A5091575574 @default.
• W2319822019 hasBestOaLocation W23198220191 @default.
• W2319822019 hasConcept C114851261 @default.
• W2319822019 hasConcept C126322002 @default.
• W2319822019 hasConcept C142462285 @default.
• W2319822019 hasConcept C159047783 @default.
• W2319822019 hasConcept C203014093 @default.
• W2319822019 hasConcept C2522874641 @default.
• W2319822019 hasConcept C2776317777 @default.
• W2319822019 hasConcept C2776824251 @default.
• W2319822019 hasConcept C2777965375 @default.
• W2319822019 hasConcept C2779820661 @default.
• W2319822019 hasConcept C2780252810 @default.
• W2319822019 hasConcept C2911091166 @default.
• W2319822019 hasConcept C71924100 @default.
• W2319822019 hasConcept C86803240 @default.
• W2319822019 hasConcept C89423630 @default.
• W2319822019 hasConceptScore W2319822019C114851261 @default.
• W2319822019 hasConceptScore W2319822019C126322002 @default.
• W2319822019 hasConceptScore W2319822019C142462285 @default.
• W2319822019 hasConceptScore W2319822019C159047783 @default.
• W2319822019 hasConceptScore W2319822019C203014093 @default.
• W2319822019 hasConceptScore W2319822019C2522874641 @default.
• W2319822019 hasConceptScore W2319822019C2776317777 @default.
• W2319822019 hasConceptScore W2319822019C2776824251 @default.
• W2319822019 hasConceptScore W2319822019C2777965375 @default.
• W2319822019 hasConceptScore W2319822019C2779820661 @default.
• W2319822019 hasConceptScore W2319822019C2780252810 @default.
• W2319822019 hasConceptScore W2319822019C2911091166 @default.
• W2319822019 hasConceptScore W2319822019C71924100 @default.
• W2319822019 hasConceptScore W2319822019C86803240 @default.
• W2319822019 hasConceptScore W2319822019C89423630 @default.
• W2319822019 hasIssue "10S" @default.
• W2319822019 hasLocation W23198220191 @default.
• W2319822019 hasLocation W23198220192 @default.
• W2319822019 hasOpenAccess W2319822019 @default.
• W2319822019 hasPrimaryLocation W23198220191 @default.
• W2319822019 hasRelatedWork W1999277080 @default.
• W2319822019 hasRelatedWork W2004766863 @default.
• W2319822019 hasRelatedWork W2083465008 @default.
• W2319822019 hasRelatedWork W2085681409 @default.
• W2319822019 hasRelatedWork W2116654551 @default.
• W2319822019 hasRelatedWork W2439601139 @default.
• W2319822019 hasRelatedWork W2803971090 @default.
• W2319822019 hasRelatedWork W2895562368 @default.
• W2319822019 hasRelatedWork W2952121670 @default.
• W2319822019 hasRelatedWork W4283320410 @default.
• W2319822019 hasVolume "94" @default.
• W2319822019 isParatext "false" @default.
• W2319822019 isRetracted "false" @default.
• W2319822019 magId "2319822019" @default.
• W2319822019 workType "article" @default.